110 related articles for article (PubMed ID: 18471786)
21. Effect of androgen deprivation therapy on prostatic intraepithelial neoplasia.
Bostwick DG; Qian J
Urology; 2001 Aug; 58(2 Suppl 1):91-3. PubMed ID: 11502458
[TBL] [Abstract][Full Text] [Related]
22. [Is tumour grade applicable to finasteride-treated prostate cancer?].
Molinié V; Ruffion A; Allory Y; Leroy X; Cochand Priollet B; Paraf F; de la Taille A
Prog Urol; 2005 Jun; 15(3):387-91. PubMed ID: 16097140
[TBL] [Abstract][Full Text] [Related]
23. Secondary hormonal therapy.
Smith DC
Semin Urol Oncol; 1997 Feb; 15(1):3-12. PubMed ID: 9050134
[TBL] [Abstract][Full Text] [Related]
24. Secondary hormonal therapy for advanced prostate cancer.
Lam JS; Leppert JT; Vemulapalli SN; Shvarts O; Belldegrun AS
J Urol; 2006 Jan; 175(1):27-34. PubMed ID: 16406864
[TBL] [Abstract][Full Text] [Related]
25. Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5alpha-reductase.
Vis AN; Schröder FH
BJU Int; 2009 Nov; 104(9):1191-7. PubMed ID: 19624596
[TBL] [Abstract][Full Text] [Related]
26. Androgen annihilation as a new therapeutic paradigm in advanced prostate cancer.
Rove KO; Crawford ED
Curr Opin Urol; 2013 May; 23(3):208-13. PubMed ID: 23492838
[TBL] [Abstract][Full Text] [Related]
27. Maximal androgen blockade for advanced prostate cancer.
Klotz L
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):331-40. PubMed ID: 18471790
[TBL] [Abstract][Full Text] [Related]
28. A potential paradox in prostate adenocarcinoma progression: oestrogen as the initiating driver.
Singh PB; Matanhelia SS; Martin FL
Eur J Cancer; 2008 May; 44(7):928-36. PubMed ID: 18381236
[TBL] [Abstract][Full Text] [Related]
29. What is the role of androgen deprivation therapy in the treatment of locally advanced prostate cancer?
Kollmeier MA; Zelefsky MJ
Nat Clin Pract Urol; 2008 Nov; 5(11):584-5. PubMed ID: 18813218
[TBL] [Abstract][Full Text] [Related]
30. Combined hormone therapy and radiation therapy for locally advanced prostate cancer.
Bolla M; Laramas M;
Crit Rev Oncol Hematol; 2012 Dec; 84 Suppl 1():e30-4. PubMed ID: 21144766
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical changes in prostate cancer after androgen deprivation therapy.
Bostwick DG
Mol Urol; 2000; 4(3):101-6;discussion 107. PubMed ID: 11062363
[TBL] [Abstract][Full Text] [Related]
32. Mechanisms leading to the development of hormone-resistant prostate cancer.
Kasper S; Cookson MS
Urol Clin North Am; 2006 May; 33(2):201-10, vii. PubMed ID: 16631458
[TBL] [Abstract][Full Text] [Related]
33. Managing prostate cancer: the role of hormone therapy.
Ramirez ML; Keane TE; Evans CP
Can J Urol; 2007 Dec; 14 Suppl 1():10-8. PubMed ID: 18163939
[TBL] [Abstract][Full Text] [Related]
34. Molecular profiles of finasteride effects on prostate carcinogenesis.
Li J; Kim J
Cancer Prev Res (Phila); 2009 Jun; 2(6):518-24. PubMed ID: 19491289
[TBL] [Abstract][Full Text] [Related]
35. Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy.
Israeli RS; Ryan CW; Jung LL
J Urol; 2008 Feb; 179(2):414-23. PubMed ID: 18076933
[TBL] [Abstract][Full Text] [Related]
36. Incidence and management of gynecomastia in men treated for prostate cancer.
Dobs A; Darkes MJ
J Urol; 2005 Nov; 174(5):1737-42. PubMed ID: 16217274
[TBL] [Abstract][Full Text] [Related]
37. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
Vis AN; Schröder FH
BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms of prostate cancer progression to androgen independence.
McPhaul MJ
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):373-88. PubMed ID: 18471793
[TBL] [Abstract][Full Text] [Related]
39. Current status and prospects of androgen depletion therapy for prostate cancer.
Akaza H
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):293-302. PubMed ID: 18471787
[TBL] [Abstract][Full Text] [Related]
40. Stepping-stones to the further advancement of androgen-deprivation therapy for prostate cancer.
Nishiyama T; Suzuki K; Yamana K; Tonegawa E; Wako K; Takahashi K
Expert Rev Anticancer Ther; 2006 Feb; 6(2):259-68. PubMed ID: 16445378
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]